Back to Browse Journals » Vascular Health and Risk Management » Volume 7

Pre-eclampsia: pathophysiology, diagnosis, and management

Authors Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi J-M

Published 19 July 2011 Volume 2011:7 Pages 467—474

DOI http://dx.doi.org/10.2147/VHRM.S20181

Review by Single-blind

Peer reviewer comments 3

Jennifer Uzan1, Marie Carbonnel1, Olivier Piconne1,3, Roland Asmar2, Jean-Marc Ayoubi1
1Department of Gynecology and Obstetrics, Hôpital Foch, Suresnes, France; 2Foundation Medical Research Institutes, Geneva, Switzerland; 3Department of Gynecology and Obstetrics, Hôpital Antoine Béclère, Clamart, France

Abstract: The incidence of pre-eclampsia ranges from 3% to 7% for nulliparas and 1% to 3% for multiparas. Pre-eclampsia is a major cause of maternal mortality and morbidity, preterm birth, perinatal death, and intrauterine growth restriction. Unfortunately, the pathophysiology of this multisystem disorder, characterized by abnormal vascular response to placentation, is still unclear. Despite great polymorphism of the disease, the criteria for pre-eclampsia have not changed over the past decade (systolic blood pressure >140 mmHg or diastolic blood pressure ≥90 mmHg and 24-hour proteinuria ≥0.3 g). Clinical features and laboratory abnormalities define and determine the severity of pre-eclampsia. Delivery is the only curative treatment for pre-eclampsia. Multidisciplinary management, involving an obstetrician, anesthetist, and pediatrician, is carried out with consideration of the maternal risks due to continued pregnancy and the fetal risks associated with induced preterm delivery. Screening women at high risk and preventing recurrences are key issues in the management of pre-eclampsia.

Keywords: pre-eclampsia, epidemiology, pathophysiology, therapeutic management

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Other article by this author:

Short-term outcome of patients with preeclampsia

Koual M, Abbou H, Carbonnel M, Picone O, Ayoubi JM

Vascular Health and Risk Management 2013, 9:143-148

Published Date: 15 April 2013

Readers of this article also read:

Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer

Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle RB, Guzman R, Pagel MD, Meuillet EJ

International Journal of Nanomedicine 2014, 9:5653-5665

Published Date: 3 December 2014

Surgical therapies for corneal perforations: 10 years of cases in a tertiary referral hospital

Yokogawa H, Kobayashi A, Yamazaki N, Masaki T, Sugiyama K

Clinical Ophthalmology 2014, 8:2165-2170

Published Date: 29 October 2014

Is increasing the dose of Entecavir effective in partial virological responders?

Erturk A, Adnan Akdogan R, Parlak E, Cure E, Cumhur Cure M, Ozturk C

Drug Design, Development and Therapy 2014, 8:621-625

Published Date: 29 May 2014

Association of age and macular pigment optical density using dual-wavelength autofluorescence imaging

Lima VC, Rosen RB, Prata TS, Dorairaj S, Spielberg L, Maia M, Sallum JM

Clinical Ophthalmology 2013, 7:685-690

Published Date: 4 April 2013

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L, Haas S

Vascular Health and Risk Management 2012, 8:363-370

Published Date: 1 June 2012

Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future

Sinha R, Nastoupil LJ, Flowers CR

Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:87-98

Published Date: 19 April 2012

Update on pediatric dystonias: etiology, epidemiology, and management

Fernández-Alvarez E, Nardocci N

Degenerative Neurological and Neuromuscular Disease 2012, 2:29-41

Published Date: 12 April 2012

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012